News

Genzyme has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a new oral therapy for Gaucher disease type 1. Reportedly, the two

The FDA has granted 510(k) clearance to Abbott for an antibody cyclic-citrulinated peptide, or anti-CCP assay, to run on the world class systems. The company said that by

Bristol-Myers Squibb has reported that new clinical data support continued development of a subcutaneous administration of Orencia (abatacept) for patients with moderate to severe rheumatoid arthritis. Reportedly, the

MorphoSys has enter into a new alliance with Daiichi Sankyo in the discovery and development of therapeutic antibodies for hospital-acquired (nosocomial) infections. Daiichi Sankyo becomes MorphoSys’s first collaborator

Mylan has announced that two of its subsidiaries have resolved a longstanding dispute with the US Department of Justice relating to certain Medicaid rebate classifications. Mylan’s subsidiaries Mylan

Hydra Biosciences has entered into an agreement with Cubist Pharmaceuticals for a joint collaboration to develop novel ion channel drugs. The deal focuses on Hydra’s research and development

AVX Corporation (AVX) and Cabot have announced the resolution of all outstanding litigation between the parties relating to the supply of tantalum by Cabot to AVX. The terms

SIRO Clinpharm, a contract research organisation (CRO) with its base in India, US, Europe and Israel has announced expansion of its Clinical Trials Supplies facility in Mumbai, India.

Abbott has introduced ZonePerfect Indulgence Nutrition Squares, a new snack with a soft, whipped center. ZonePerfect Indulgence squares are available in three flavors: Chocolate Peanut Butter Mousse, Caramel